# OP IPILIMUMAB / NIVOLUMAB - MELANOMA

Types: ONCOLOGY TREATMENT

Synonyms: NEEV, OPDI, NIVO, IPILIMUMAB, EPI, YERVOY, NIVOLUMAB, OPDIVO, MELANOMA, SKIN

| Cycles | s 1 to | 4     | Repea                         | t 4 times                  | Cycle length: 21 days  |                        |  |
|--------|--------|-------|-------------------------------|----------------------------|--|------------------------|--|
|        | Day    |       | _                             |                            |  | Perform every 1 day x1 |  |
|        |        | Appoi | ntment Requests               | MENT DECLIECT              |  |                        |  |
|        |        |       | INFUSION APPOINT<br>Interval: | Occurrences:               |  |                        |  |
|        |        | Labs  | intorvan.                     | Cocarronoco.               |  |                        |  |
|        |        | Laus  | □ CDC WITH DI ATEL            | ET AND DIFFEREN            | FIAI   |                        |  |
|        |        |       | ☑ CBC WITH PLATEL             |                            | IIAL   |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       |                               | METABOLIC PANEI            | -  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | ✓ MAGNESIUM LEVE              | L                          |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | ✓ THYROID STIMULATING HORMONE |                            |  |                        |  |
|        |        | Outpa | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       |                               | O COUNT ON COOL            |  |                        |  |
|        |        |       |                               | 0                          |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | ☑ T4, FREE                    |                            |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | □ LDH                         |                            |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | ☐ URIC ACID LEVEL             |                            |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               |  |                        |  |
|        |        |       | tient Electrolyte Replacer    | ment Protocol              |  |                        |  |
|        |        |       | TREATMENT CONDITIONS 39       |                            |  |                        |  |
|        |        |       | Interval:<br>Comments:        | Occurrences:               | actions 2 E to E OmEa/L)                                       |                        |  |
|        |        |       | Comments.                     |                            | nal range 3.5 to 5.0mEq/L)<br>applies for SCr less than 1.5. O | therwise, contact      |  |
|        |        |       |                               | MD/NP                      |  |                        |  |
|        |        |       |                               |                            | applies only to same day lab va                                |                        |  |
|        |        |       |                               | o Serum p PO and contact I | otassium less than 3.0mEq/L, g                                 | ive 40mEq KGL IV or    |  |
|        |        |       |                               |                            | otassium 3.0 to 3.2mEq/L, give                                 | 40mEq KCL IV or PO     |  |
|        |        |       |                               |                            | otassium 3.3 to 3.4mEq/L, give                                 |                        |  |
|        |        |       |                               | o Serum p<br>replacement   | otassium 3.5 mEq/L or greater,                                 | do not give potassium  |  |
|        |        |       |                               |                            | meets criteria, order SmartSet                                 | called "Outpatient     |  |
|        |        |       |                               | Electrolyte Repla          | cement"  | ·                      |  |
|        |        |       |                               | o Sign electronic          | ctrolyte replacement order as Pe                               | er protocol: cosign    |  |
|        |        |       |                               | roquirou                   |  |                        |  |
|        |        |       | TREATMENT CONDITIONS 40       |                            |  |                        |  |
|        |        |       | Interval:                     | Occurrences:               | mal range 1.6 to 2.6 m Fa/L)                                   |                        |  |
|        |        |       | Comments:                     |                            | mal range 1.6 to 2.6mEq/L)<br>applies for SCr less than 1.5. O | therwise, contact      |  |
|        |        |       |                               | 2 11010001                 |  |                        |  |

MD/NP

o Protocol applies only to same day lab value.

o Serum Magnesium less than 1.0mEq/L, give 2 gram magnesium sulfate IV and contact MD/NP

o Serum Magnesium 1.0 to 1.2mEq/L, give 2 gram magnesium sulfate IV

o Serum Magnesium 1.3 to 1.5mEq/L, give 1 gram magnesium sulfate IV

o Serum Magnesium 1.6 mEq/L or greater, do not give

magnesium replacement

o If patient meets criteria, order SmartSet called "Outpatient Electrolyte Replacement"

o Sign electrolyte replacement order as Per protocol: cosign required

### **Nursing Orders**

### **TREATMENT CONDITIONS 11**

Interval: -- Occurrences: --

Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than

100,000; AST or ALT > 3 and up to 5x Upper Normal Limit or Total Bilirubin > 1.5 and up to 3x Upper Normal Limit; Creatinine > 1.5 and up

to 6x Upper Normal Limit or > 1.5x from baseline.

### Line Flush

sodium chloride 0.9 % flush 20 mL

Dose: 20 mL Route: intravenous PRN

Start: S

### **Nursing Orders**

sodium chloride 0.9 % infusion 250 mL

Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose

Start: S Instructions:

To keep vein open.

### Chemotherapy

nivolumab (OPDIVO) 1 mg/kg in sodium chloride 0.9% 100 mL IVPB

Dose: 1 mg/kg Route: intravenous once

once over 30 Minutes for 1 dose

Offset: 30 Minutes

Instructions:

Administer with low protein binding 0.22 micron in-line filter. Do not shake. Do not mix with other medications. Flush IV line with NS at the

end of infusion.

Ingredients: Name Type Dose Selected Adds Vol.

NIVOLUMAB 100 Medications 1 mg/kg Main Yes MG/10 ML Ingredient INTRAVENOUS SOLUTION SODIUM QS Base 100 mL Yes Yes CHLORIDE 0.9 % INTRAVENOUS

ipilimumab (YERVOY) 3 mg/kg in sodium

chloride 0.9% chemo IVPB

Dose: 3 mg/kg Route: intravenous once over 90 Minutes for 1 dose

SOLUTION

Offset: 90 Minutes

Instructions:

Administer through a 0.2 or 0.22 micron inline

filter.

Ingredients: Name Type Dose Selected Adds Vol.

IPILIMUMAB 50 Medications 3 mg/kg Main Yes MG/10 ML (5 Ingredient

MG/ML)

INTRAVENOUS SOLUTION

SODIUM Base Yes Yes

CHLORIDE 0.9 % INTRAVENOUS SOLUTION

DEXTROSE 5 % IN Base No Yes

WATER (D5W) INTRAVENOUS SOLUTION

### Hematology & Oncology Hypersensitivity Reaction Standing Order

### **ONC NURSING COMMUNICATION 82**

Interval: -- Occurrences: --

Comments: Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms

only – itching, flushing, periorbital edema, rash, or runny nose)

1. Stop the infusion.

2. Place the patient on continuous monitoring.

3. Obtain vital signs.

4. Administer Normal Saline at 50 mL per hour using a new bag and new

intravenous tubing.

5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous

once.

6. If less than 30 minutes since the last dose of Diphenhydramine, administer Fexofenadine 180 mg orally and Famotidine 20 mg

intravenous once.

7. Notify the treating physician.

8. If no improvement after 15 minutes, advance level of care to Grade 2

(Moderate) or Grade 3 (Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or

otherwise ordered by covering physician.

### **ONC NURSING COMMUNICATION 4**

Interval: -- Occurrences: --

Comments: Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or

gastrointestinal symptoms – shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or

back pain)

1. Stop the infusion.

2. Notify the CERT team and treating physician immediately.

3. Place the patient on continuous monitoring.

4. Obtain vital signs.

5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to

maintain O2 saturation of greater than or equal to 92%.

6. Administer Normal Saline at 150 mL per hour using a new bag and

new intravenous tubing.

7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy

to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg

intravenous once.

8. If no improvement after 15 minutes, advance level of care to Grade 3

(Severe).

9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

#### **ONC NURSING COMMUNICATION 83**

Interval: -- Occurrences: --

Comments: Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic

compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

- 1. Stop the infusion.
- 2. Notify the CERT team and treating physician immediately.
- 3. Place the patient on continuous monitoring.
- 4. Obtain vital signs.
- 5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
- 6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
- 7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
- 8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
- 9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
- 10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

## diphenhydrAMINE (BENADRYL) injection 25

mg

Dose: 25 mg Route: intravenous PRN

Start: S

fexofenadine (ALLEGRA) tablet 180 mg

Dose: 180 mg Route: oral PRN

Start: S

famotidine (PEPCID) 20 mg/2 mL injection 20

mg

Dose: 20 mg Route: intravenous PRN

Start: S

hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg

Dose: 100 mg Route: intravenous PRN

dexamethasone (DECADRON) injection 4 mg

Dose: 4 mg Route: intravenous PRN

Start: S

epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT

injection syringe 0.3 mg

Dose: 0.3 mg Route: subcutaneous PRN

Start: S

Discharge Nursing Orders

**ONC NURSING COMMUNICATION 76** 

Interval: -- Occurrences: -- Comments: Discontinue IV.

Discharge Nursing Orders

Dose: 20 mL Route: intravenous PRN

☑ HEParin, porcine (PF) injection 500 Units

Dose: 500 Units Route: intra-catheter once PRN

Start: S Instructions:

Concentration: 100 units/mL. Heparin flush for

Implanted Vascular Access Device

maintenance.